Published in Clin Cancer Res on June 10, 2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets (2012) 1.33
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (2011) 1.10
Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol (2011) 1.07
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther (2012) 1.05
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer (2012) 1.03
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A (2015) 0.96
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One (2014) 0.93
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid (2013) 0.91
Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med (2014) 0.89
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther (2013) 0.89
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis (2014) 0.89
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol (2012) 0.88
From modules to medicine: How modular domains and their associated networks can enable personalized medicine. FEBS Lett (2012) 0.86
Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention. Front Psychiatry (2014) 0.86
Manipulating the apoptotic pathway: potential therapeutics for cancer patients. Br J Clin Pharmacol (2013) 0.86
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One (2014) 0.85
Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One (2014) 0.84
Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget (2016) 0.83
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner. Oncotarget (2015) 0.81
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol (2014) 0.81
Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo. Oncotarget (2015) 0.81
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol (2014) 0.81
RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol (2011) 0.80
Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members. Cell Death Dis (2013) 0.80
Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments. Antimicrob Agents Chemother (2017) 0.78
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma. Int J Mol Sci (2015) 0.78
Targeted Therapies in Adult B-Cell Malignancies. Biomed Res Int (2015) 0.76
Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKL. Mol Cells (2015) 0.75
PPIMpred: a web server for high-throughput screening of small molecules targeting protein-protein interaction. R Soc Open Sci (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Apoptosis-targeted therapies for cancer. Cancer Cell (2003) 2.67
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood (2007) 2.20
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood (2007) 2.14
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol (2007) 1.49
Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. J Neurophysiol (2007) 1.29
Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med (2001) 1.17
Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia (2009) 1.09
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol (2003) 4.34
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol (2008) 3.83
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2011) 1.75
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol (2003) 1.71
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol (2005) 1.69
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 1.52
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol (2007) 1.49
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma (2012) 1.47
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction. Oncology (Williston Park) (2016) 1.44
Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leuk Lymphoma (2014) 1.43
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat (2012) 1.43
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res (2008) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma (2012) 1.40
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. Eur J Haematol (2014) 1.39
Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma (2015) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 1.33
Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis (2013) 1.31
Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol (2005) 1.31
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol (2007) 1.28
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Case report: Lung disease in World Trade Center responders exposed to dust and smoke: carbon nanotubes found in the lungs of World Trade Center patients and dust samples. Environ Health Perspect (2010) 1.27
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.26
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics (2008) 1.23
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol (2010) 1.23
Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr (2004) 1.22
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res (2008) 1.18
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol (2013) 1.18
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med (2012) 1.18
Ocular toxicity of targeted therapies. J Clin Oncol (2012) 1.17
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Small bowel adenocarcinoma. Curr Treat Options Oncol (2009) 1.13
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol (2011) 1.13
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol (2012) 1.12
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One (2011) 1.12
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep (2007) 1.12
Safety of capecitabine: a review. Expert Opin Drug Saf (2010) 1.11
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol (2003) 1.11
Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol (2008) 1.11
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol (2007) 1.11
Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer (2009) 1.09
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res (2009) 1.08
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 1.08
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res (2011) 1.07
Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol (2007) 1.07
Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism. Cancer Res (2013) 1.07
Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol Blood Marrow Transplant (2007) 1.06
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol (2008) 1.05
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res (2007) 1.05
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2007) 1.04